🔥Telegram İfşa

#GU23 ASCO Much awaited data from the ph3 Propel shows continued rPFS benefits + strong trend for OS (7 month) benefit with abiraterone + olaparib vs. abiraterone in 1st line mCRPC in HRR pos & neg #prostatecancer 👇 OncoAlert PCF Science Med-IQ #MedIQGU23

Darolutamide- Real world safety data in nmCRPC!! Efficacy data with more than 100 patients coming soon. #GU23

Translation of Prognostic and Pharmacodynamic Biomarkers from Trial to Non-trial Patients with Metastatic Castratio… Thiraviyam Elumalai pubmed.ncbi.nlm.nih.gov/35314092/

Excellent opportunity!!

Very much looking forward to introducing our brilliant 2 oncology specialties to some bright young things. We still have places available!

Grandslam No: 23 loading for Djokovic.. Alcaraz trying to defy history Get your popcorn ready The match of the year

Wondered whether to use RT in cN+ prostate ca? Our 🇬🇧 multi-centre study now published in @RadiotherapyOn1 #greenjournal suggests to do so! #pcsm #radonc Thiraviyam Elumalai ➡️ thegreenjournal.com/article/S0167-…

Led by Thiraviyam Elumalai Priyamvada Maitre 👏🏽👏🏽👏🏽🥳 Manchester Cancer Research Centre Division of Cancer Sciences Christie Library @TheChristieSoO ESTRO @RadiotherapyOn1

RT dose variations in the apex and base of prostate could predict recurrence ( HDR boost patients) Thought provoking 612 patients- voxel based data-mining work Read our paper doi.org/10.3389/fonc.2…

Radiotherapy for node+ #prostatecancer: If not doing already, please do! Improves OS, no systemic side effects, cost effective Our UK multicentre study out in @RadiotherapyOn1 FREE download till 11 Aug 23👇🏽 authors.elsevier.com/c/1hIMfcA0-EhhO BIG thanks Prof Ananya💙 @achoud72.bsky.social #whereishoskin #pcsm

Tune in ⁦to ⁦BBC Newsnight⁩ 7pm tonight to watch my colleague & mentor ⁦@ml4cancer⁩ speaks about AI in RT ⁦Cambridge University Hospitals NHS⁩ ⁦⁦CRUK RadNet Cambridge ⁦The Royal College of Radiologists ⁦⁦➡️AI cuts treatment time for cancer radiotherapy bbc.co.uk/news/health-65…

New research: The role of irradiation in the management of the axilla in early breast cancer patients: The need for axillary radiotherapy in patients with invasive breast cancer (IBC) has been a topic of great debate in the last decade.… #oncology frontiersin.org/articles/10.33…

Thrilled to be able to share our Journal of Clinical Oncology paper on survival outcomes for patients diagnosed with clinically node positive nonmetastatic bladder cancer. ascopubs.org/doi/full/10.12…

The end of Aidan J Murray two week elective was celebrated with a lovely dinner 🍴hosted by CRUK RadNet Cambridge Great food and warm conversations filled the evening. 🌟🌟🌟#RadNet

ஈன்ற பொழுதின் பெரிதுவக்கும் தன்மகனைச் சான்றோன் எனக்கேட்ட தாய். #Praggnanandhaa #magnuscarlsen

We lost a good human 😞

Good morning Kerala International workshop on breast cancer addressing 100s of trainees from India!! Well done Regional cancer centre- Trivandrum.

Results of our Phase III RCT of addition of Triple OMCT to Chemotherapy in platinum sensitive HNSCC. Both significant PFS and OS benefit, somewhat similar to CETUXI. Immediately practice changing for those who can't afford IO/Cetuximab. The ASCO Post Bipinesh Sansar Common Sense Oncology Dr Amol Akhade

Here CRUK Cambridge Centre we are at the forefront of surgical oncology research, in partnership with patients like Andrew, and AstraZeneca. Thanks to them and funders supporting our mission to create a world free from the fear of #prostatecancer Prostate Cancer Foundation ProstateCancerResearch Cancer Research UK Prostate Cancer UK

It’s been an honour sharing stage with you Nuradh Joseph Excellent talk on the cost effectiveness in bladder cancer treatment!! Hoping to see you soon